Sutro Biopharma Announces 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance.

Sutro Biopharma's Board of Directors has approved a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse stock split will become effective on December 3, 2025, and Sutro's common stock will trade under a new CUSIP number. This move aims to address the company's current low stock price.